Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn’s Disease, a Randomized Controlled Trial
- 2.4k Downloads
Cannabidiol (CBD) is an anti-inflammatory cannabinoid shown to be beneficial in a mouse model of IBD. Lacking any central effect, cannabidiol is an attractive option for treating inflammatory diseases.
To assess the effects of cannabidiol on Crohn’s disease in a randomized placebo-controlled trial.
Patients and Methods
Twenty patients aged 18–75 years with a Crohn’s disease activity index (CDAI) >200 were randomized to receive oral (10 mg) CBD or placebo twice daily. Patients did not respond to standard treatment with steroids (11 patients), thiopurines (14), or TNF antagonists (11). Disease activity and laboratory parameters were assessed during 8 weeks of treatment and 2 weeks thereafter. Other medical treatment remained unchanged.
Of 20 patients recruited 19 completed the study. Their mean age was 39 ± 15, and 11 were males. The average CDAI before cannabidiol consumption was 337 ± 108 and 308 ± 96 (p = NS) in the CBD and placebo groups, respectively. After 8 weeks of treatment, the index was 220 ± 122 and 216 ± 121 in the CBD and placebo groups, respectively (p = NS). Hemoglobin, albumin, and kidney and liver function tests remained unchanged. No side effects were observed.
In this study of moderately active Crohn’s disease, CBD was safe but had no beneficial effects. This could be due to lack of effect of CBD on Crohn’s disease, but could also be due to the small dose of CBD, the small number of patients in the study, or the lack of the necessary synergism with other cannabinoids. Further investigation is warranted.
KeywordsCannabidiol Cannabis Crohn’s disease Inflammatory bowel disease
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 5.Naftali T, Lev LB, Yablecovitch D, Half E, Konikoff FM. Treatment of Crohn’s disease with cannabis: an observational study. [Erratum appears in Isr Med Assoc J. 2011;13:582 Note: Yablekovitz, Doron (corrected to Yablecovitch, Doron)]. Isr Med Assoc J IMAJ. 2011;13:455–458.Google Scholar
- 12.Esposito G, De Filippis D, Cirillo C, et al. Cannabidiol in inflammatory bowel diseases: a brief overview. Phyther Res. 2012;2013:633–636.Google Scholar
- 15.Kozela E, Pietr M, Juknat A, Rimmerman N, Levy R, Vogel Z. Cannabinoids delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells. J Biol Chem. 2010;285:1616–1626.CrossRefPubMedGoogle Scholar
- 25.Hawksworth G, McArdle K. Metabolism and pharmacokinetics of cannabinoids. In: Guy GC, Robson PJ, Whittle BA, eds. The Medicinal Uses of Cannabis and Cannabinoids. London: London Pharmaceutical Press; 2004:205–228.Google Scholar